ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Petition Filed To Revoke NlH License To Use Radioactive Materials

October 20, 1995

Clinton R&D Budget Amounts to a Cut, AAAS Study Says

April 18, 1997

Workshop concludes HPV Vaccines Would Be Valuable, Feasible

April 8, 1988

BCDDP “Major Accomplishment” Described By ACS’ Holleb

July 21, 1978

Tom Harkin Is New Chairman f Senate Labor-HS-Education Subcommittee

January 13, 1989

Samuel Waksal Resigns From ImClone Following Unimpressive ASCO Presentation

May 24, 2002